Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab effectiveness in idiopathic membranous nephropathy
ChiCTR2500109296Phase 4Completed
- Sponsor
- Affiliated Hospital of Shandong Second Medical University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in idiopathic membranous glomerulonephritis (IMG), sponsored by Affiliated Hospital of Shandong Second Medical University. Primary endpoint: Clinical efficacy rate at 6, 12, and 24 months. Started Sep 2025; status: completed.
02
Drugs
rituximab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2500109296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109296.